|
Galapagos NV (GLPG) DCF -Bewertung
BE | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Galapagos NV (GLPG) Bundle
Bewerten Sie die finanziellen Aussichten von Galapagos NV wie ein Experte! Dieser (GLPG) DCF-Taschenrechner verfügt über vorgefüllte Finanzdaten und bietet Ihnen die Flexibilität, das Umsatzwachstum, WACC, Margen und andere wichtige Annahmen zu ändern, um sich mit Ihren Vorhersagen auszurichten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 878.1 | 496.8 | 503.9 | 525.1 | 249.1 | 192.9 | 149.3 | 115.6 | 89.5 | 69.3 |
| Revenue Growth, % | 0 | -43.42 | 1.42 | 4.21 | -52.56 | -22.59 | -22.59 | -22.59 | -22.59 | -22.59 |
| EBITDA | 388.9 | -306.1 | -104.9 | -34.7 | 53.0 | -9.0 | -7.0 | -5.4 | -4.2 | -3.2 |
| EBITDA, % | 44.29 | -61.61 | -20.82 | -6.6 | 21.29 | -4.69 | -4.69 | -4.69 | -4.69 | -4.69 |
| Depreciation | 11.2 | 17.7 | 22.1 | 31.1 | 45.4 | 12.9 | 10.0 | 7.7 | 6.0 | 4.6 |
| Depreciation, % | 1.28 | 3.55 | 4.39 | 5.92 | 18.21 | 6.67 | 6.67 | 6.67 | 6.67 | 6.67 |
| EBIT | 377.7 | -323.7 | -127.0 | -65.7 | 7.7 | -21.9 | -17.0 | -13.1 | -10.2 | -7.9 |
| EBIT, % | 43.01 | -65.16 | -25.21 | -12.52 | 3.08 | -11.36 | -11.36 | -11.36 | -11.36 | -11.36 |
| Total Cash | 6,007.4 | 5,363.8 | 4,887.5 | 4,254.5 | 3,828.9 | 192.9 | 149.3 | 115.6 | 89.5 | 69.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 83.2 | 180.2 | 133.6 | 80.4 | 68.2 | 44.3 | 34.3 | 26.6 | 20.6 | 15.9 |
| Account Receivables, % | 9.48 | 36.27 | 26.52 | 15.31 | 27.39 | 22.99 | 22.99 | 22.99 | 22.99 | 22.99 |
| Inventories | .3 | .4 | 21.4 | 55.0 | 76.9 | 17.6 | 13.6 | 10.6 | 8.2 | 6.3 |
| Inventories, % | 0.03017801 | 0.07425955 | 4.24 | 10.47 | 30.86 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 |
| Accounts Payable | 148.1 | 178.0 | 139.6 | 138.5 | 139.9 | 62.9 | 48.7 | 37.7 | 29.2 | 22.6 |
| Accounts Payable, % | 16.87 | 35.84 | 27.7 | 26.38 | 56.17 | 32.59 | 32.59 | 32.59 | 32.59 | 32.59 |
| Capital Expenditure | -47.5 | -94.9 | -60.1 | -38.4 | -20.0 | -20.0 | -15.5 | -12.0 | -9.3 | -7.2 |
| Capital Expenditure, % | -5.41 | -19.1 | -11.94 | -7.31 | -8.04 | -10.36 | -10.36 | -10.36 | -10.36 | -10.36 |
| Tax Rate, % | -3663.5 | -3663.5 | -3663.5 | -3663.5 | -3663.5 | -3663.5 | -3663.5 | -3663.5 | -3663.5 | -3663.5 |
| EBITAT | 377.1 | -325.0 | -129.5 | -66.6 | 289.2 | -21.9 | -17.0 | -13.1 | -10.2 | -7.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 405.5 | -469.4 | -180.4 | -55.3 | 306.2 | -23.0 | -22.7 | -17.5 | -13.6 | -10.5 |
| WACC, % | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -76.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -11 | |||||||||
| Terminal Value | -352 | |||||||||
| Present Terminal Value | -275 | |||||||||
| Enterprise Value | -352 | |||||||||
| Net Debt | -163 | |||||||||
| Equity Value | -189 | |||||||||
| Diluted Shares Outstanding, MM | 66 | |||||||||
| Equity Value Per Share | -2.87 |
What You Will Get
- Real GLPG Financial Data: Pre-filled with Galapagos NV’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Galapagos NV’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- 🔍 Real-Life GLPG Financials: Pre-filled historical and projected data for Galapagos NV.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Galapagos’ intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Galapagos’ valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Obtain the ready-to-use Excel file containing Galapagos NV’s (GLPG) financial data.
- Customize: Modify forecasts, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate multiple projections and compare results instantly.
- Make Decisions: Utilize the valuation outcomes to inform your investment strategy.
Why Choose This Calculator for Galapagos NV (GLPG)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Parameters: Adjust inputs effortlessly to suit your financial analysis.
- Real-Time Feedback: Observe immediate updates to Galapagos NV’s valuation as you tweak inputs.
- Pre-Configured: Comes with Galapagos NV’s actual financial metrics for swift evaluation.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use Galapagos NV (GLPG)?
- Investors: Make informed decisions with a robust analysis of Galapagos NV's market potential.
- Financial Analysts: Streamline your research with comprehensive data on Galapagos NV's financial performance.
- Pharmaceutical Consultants: Tailor the insights for client presentations or strategic reports focused on biotech.
- Biotech Enthusiasts: Enhance your knowledge of drug development and market dynamics using Galapagos NV as a case study.
- Researchers and Students: Utilize it as a resource for in-depth studies in biotechnology and finance-related disciplines.
What the Template Contains
- Pre-Filled Data: Contains Galapagos NV's historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for WACC calculations based on user-defined inputs.
- Key Financial Ratios: Assess Galapagos NV's profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.